Mass General - Division of Clinical Research

Condition

• Multiple Myeloma

Eligibility

Eligible Ages

Over 18 Years

Eligible Sex

All

Accepts Healthy Volunteers

No

Criteria

Inclusion:

- Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:

1. MM diagnosis according to the international myeloma working group (IMWG)
diagnostic criteria

2. Measurable disease at screening as assessed by central laboratory

- Received at least 3 prior lines of antimyeloma therapy including a proteasome
inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of
differentiation (CD) 38 monoclonal antibody (mAb)

- Documented evidence of progressive disease(PD) or failure to achieve a response to
the last line of therapy based on investigator's determination of response by the
IMWG criteria

- Have discontinued concurrent use of any other anticancer treatment (including
nonpalliative radiotherapy) or investigational agent

- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 to 2
at screening and immediately before the start of study treatment administration

Exclusion:

- Suspected or known allergies, hypersensitivity, or intolerance to excipients of
JNJ-79635322

- Had major surgery within 2 weeks before first dose or has planned major surgery
during study treatment phase

- Known active or prior central nervous system (CNS) involvement or exhibits clinical
signs of meningeal involvement of MM

- Participant has leptomeningeal disease

- Participant has a prior or concurrent second malignancy the natural history or
treatment of which could likely interfere with any study endpoints of safety or the
efficacy of the study treatment

Recruiting Locations

Study Contact